Travere Therapeutics (TVTX) has just put fresh clinical evidence in front of kidney specialists. New Phase 3 PROTECT biomarker data for FILSPARI in IgA nephropathy arrived as competition in this niche tightens.
Over the past few months, Travere Therapeutics’ share price has been choppy, with the stock down about 16% on a 30-day share price basis and lower by roughly 13% over 90 days, even though the year-to-date share price return is up 26.7% and the 1-year total shareholder return is 78.5%. This suggests long-term holders have already seen a very strong move, while shorter term momentum has cooled as investors reassess the risk and opportunity around FILSPARI’s growth potential and rising IgA nephropathy competition.
Spot 21 high quality undiscovered gems that, like Travere Therapeutics, are pushing fresh clinical data into the spotlight while still flying under many investors' radar.Travere Therapeutics has already rewarded patient holders, yet the recent pullback and fresh FILSPARI data reset the debate. Is the bigger move now behind the stock, or is the valuation still catching up to the story?
Most Popular Narrative: 32% Undervalued
Travere Therapeutics is trading at a last close of $50.08, while the most followed narrative assigns a central fair value of $74.14, which puts the spotlight on how much of FILSPARI’s rare kidney opportunity is already baked into today’s share price.
Expansion of FILSPARI's label to include treatment for FSGS, a rare kidney disease with no approved therapies, positions Travere for first-mover advantage in a large, underserved market if approved. This would create a new, high-margin revenue stream and significantly expand the company's addressable market. Regulatory trends remain favorable for rare disease and orphan drug development, as shown by efficient progress in sNDA reviews, label expansions, potential REMS relaxation/removal, and milestone payments for international approvals. Together, these factors are seen as improving pathways to accelerated product approvals, faster revenue realization, and enhanced pricing power.
See why 23 investors see Travere Therapeutics as 32% undervalued.
The prevailing narrative uses a 7.53% discount rate and concludes that Travere Therapeutics is trading at a 32.5% discount to this $74.14 estimate, with that gap tied directly to expectations around FILSPARI’s role in IgA nephropathy and potential FSGS expansion. It frames the opportunity as attractive but also highly dependent on one drug, regulatory follow through, and the pace of rare kidney adoption over the next several years.
Result: Fair Value of $74.14 (UNDERVALUED)
Still, the Travere Therapeutics story leans heavily on FILSPARI, so any regulatory setback or intensifying IgA nephropathy competition could quickly challenge that 32% undervaluation case.
Find out about the key risks to this Travere Therapeutics narrative.
Next Steps
That 32% undervaluation story might sound compelling, but sentiment can swing quickly and the data is right in front of you. If you want to see why some investors are optimistic about potential rewards, take a closer look at the 4 key rewards.
Looking for more investment ideas beyond Travere Therapeutics?
If you stop at Travere Therapeutics, you risk missing other opportunities with strong balance sheets, resilient income streams, or attractive upside potential highlighted by the data.
- Target durable income by scanning 5 dividend fortresses that can help anchor your portfolio when growth stories take a breather.
- Hunt for mispriced opportunities using the 27 high quality undervalued stocks that surfaces businesses the market might not be fully recognizing yet.
- Fortify your downside protection through the 30 resilient stocks with low risk scores that highlights companies with more resilient financial profiles.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com